1 - 8 of 8 articles
The Risk Evaluation and Mitigation Strategy (REMS) program designed to facilitate safer prescribing of extended‐release/long‐acting opioids cannot be sufficiently evaluated because of major flaws in the program's design, concludes a review published online Dec. 30, 2019, in JAMA Internal...
The addition of stimulants as an allowable use for State Opioid Response (SOR) grants will require a new application, which the Substance Abuse and Mental Health Services Administration (SAMHSA) is working on, ADAW has learned. The change was in the FY 2020 appropriations bill passed last month...
Narcan, the lifesaving opioid overdose reversal drug, has been the only naloxone spray allowed on the market due to an exclusivity agreement between the pharmaceutical company that owns it — Emergent BioSolutions — and the company that makes the spray device. This deal is ending thanks to New...
Last week's Preview Issue (see ADAW Jan. 6, 2020) didn't have room for all of the past‐year reflections and hopes and fears for the new year from stakeholders. We include them here. Thanks to the field leaders who responded to our request for comments.
New York Governor Andrew Cuomo's veto on Jan. 1 of a bill that would have removed prior‐authorization barriers for all formulations of buprenorphine in the Medicaid program was greeted with dismay by the Legal Action Center and others who had fought hard for it. He did, however, sign a similar...
The Community Anti‐Drug Coalitions of America National Leadership Forum will be held Feb. 3–6, 2020, in National Harbor, Maryland. For more information, go to https://www.cadca.org/news/cadcas‐national‐leadership‐forum.
Introducing Lisa K. Bernhardt, who now heads her LKB Strategies, which lobbies for public health organizations. For many, she needs no introduction: She has a long history on Capitol Hill and in the Department of Health and Human Services (HHS). Nobody on the Hill knows more about the Substance...
Happy hour at the National Institutes of Health (NIH)? You can see a video with National Institute on Alcohol Abuse and Alcoholism Director George Koob, Ph.D., of the bar lab, where researchers work on medications to block craving. You can see Koob talk about the work of Lorenzo Leggio, M.D., in...
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Sign Up Log In
To subscribe to email alerts, please log in first, or sign up for a DeepDyve account if you don’t already have one.
To get new article updates from a journal on your personalized homepage, please log in first, or sign up for a DeepDyve account if you don’t already have one.